Background Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, the
incidence of thromboembolism has been increasingly reported. The aim of this systematic …

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematologic disorder
characterized by complement-mediated hemolysis. C5 inhibitors (eculizumab/ravulizumab) …

Systemic reports on the descriptive epidemiology of non‐Hodgkin lymphoma (NHL) from
Southeast Asia are scarce. A nationwide multi‐institutional registry was conducted to compare …

Objectives Standard treatment with a thiotepa-based regimen in countries with a limited
resource is less feasible. Aims of the study were to evaluate the treatment outcome, and identify …

Germline DDX41 mutations were recently reported to cause MDS/AML and donor-derived
leukemia after transplantation. While previously described in Western countries, DDX41 …

Background: PNH is characterized by a degree of bone marrow failure and hemolysis
resulting in debilitating hemolytic anemia and an increased risk of thrombosis. Uncontrolled …

Objectives TP53 mutation is found frequently in therapy related acute myeloid leukemia (AML)/
myelodysplastic syndrome (MDS), AML and MDS patients with monosomy or complex …

Objectives We performed a feasibility study of an FDA-approved commercial ddPCR assay
to measure BCR::ABL1 in CML patients treated using TKI therapy. Methods Assay …

Introduction The therapeutic strategy and management of chronic myeloid leukemia (CML)
have rapidly improved with the discovery of effective tyrosine kinase inhibitors (TKIs) to target …

Background Cytogenetic abnormalities and mutated genes indicate the role of consolidation
therapy with hematopoietic stem cell transplantation (HSCT) or chemotherapy in acute …